Clinical Evaluation of Remicut(Emedastine Difumarate) in the Treatment of Chronic Urticaria.

DOI

Bibliographic Information

Other Title
  • 慢性じん麻疹に対するレミカットの臨床的有用性の検討　特に，症状消失日と投与終了後の持続効果について
  • 特に, 症状消失日と投与終了後の持続効果について

Description

In order to study the effectiveness, safety, and usefulness of remicut® on chronic urticaria, a multicenter open study was conducted. Forty five patients were enrolled in this study and treated with 4 mg/day of emedastine difumarate for two weeks. Results obtained were following; marked improvement in 14 (33%), moderate improvement in 14 (33%), slight improvement in 8 (19%). The final global improvement ratio was 65%. Itching or eruption (wheals and erythema) disappeared within two weeks' administration in 60.5%, 53.5% of the patients, respectively. A clinical adverse reactions, such as sleepiness, were seen in 8 patients and disappeared without symptomatic treatment. Thus, the global utility ratio was 62.2%(28/45).<BR>These results support the efficacy and safety of remicut® in management for choronic urticaria.

Journal

  • Skin research

    Skin research 38 (1), 104-110, 1996

    Meeting of Osaka Dermatological Association

Keywords

Details 詳細情報について

  • CRID
    1390001204798915072
  • NII Article ID
    130004045697
  • DOI
    10.11340/skinresearch1959.38.104
  • ISSN
    1884541X
    00181390
  • Text Lang
    ja
  • Data Source
    • JaLC
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top